Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...
January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.
Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...
The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...
This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...
Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...
Addressing Neurologic Toxicities in CAR-T Therapy: Monitoring, Management, and Patient Communication
Neurologic toxicities, such as ICANS, pose unique challenges. How do you approach monitoring and management of these events in your practice? What tools or assessment methods help you identify early ...
Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS? Which strategies have you found most effective for reducing the severity of ...
Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...
This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback